Targeting ANGPTL4/NRP1/ABL1/RAD51 Axis Reverses Cisplatin Resistance in Head and Neck Cancer

26 Mar 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

Proceedings of the National Academy of Sciences, Volume 123, Issue 13, March 2026.
SignificanceHere, we identify a molecular pathway that drives cisplatin resistance in head and neck squamous cell carcinoma (HNSCC).
The angiogenic factor angiopoietin-like 4 (ANGPTL4) engages Neuropilin1 to activate ABL1, which in turn phosphorylates and ...